The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst)
Longer follow-up for survival and safety from the EVOKE-01 trial of sacituzumab govitecan (SG) vs docetaxel in patients (pts) with metastatic non-small cell lung cancer (mNSCLC).
 
Niels Reinmuth
Consulting or Advisory Role - Amgen; AstraZeneca; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; MSD Oncology; Pfizer; Takeda
Speakers' Bureau - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Janssen Oncology; Lilly; Merck KGaA; Merck Sharp & Dohme; Pfizer; Roche; Sanofi Aventis GmbH; Takeda
Travel, Accommodations, Expenses - Janssen; Pfizer
 
Marina Garassino
Honoraria - AstraZeneca/MedImmune; Blueprint Pharmaceutic; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; GlaxoSmithKline; Medscape; MSD Oncology; Novartis; Oncohost; Pfizer; Regeneron; Revolution Medicines; Roche; Sanofi/Aventis; Takeda
Consulting or Advisory Role - Abbvie; Abion; AstraZeneca; Bayer; Bayer; Blueprint Medicines; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Daiiki Sankyo; Gilead Sciences; GlaxoSmithKline; IO Biotech; Janssen; Janssen Oncology; Lilly; Merck; Mirati Therapeutics; MSD; Novartis; Novocure; Pfizer; Regeneron; Revolution Medicines; Roche; Sanofi; Seagen; Takeda
Speakers' Bureau - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Merck; Mirati Therapeutics; MSD Oncology
Research Funding - Amgen (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); Spectrum Pharmaceuticals (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Merck; Pfizer; Roche
(OPTIONAL) Uncompensated Relationships - Merck
 
Oscar Juan-Vidal
Honoraria - Amgen; AstraZeneca/MedImmune; Janssen; Takeda
Consulting or Advisory Role - AstraZeneca Spain; Janssen Oncology; Lilly; Merck; Roche/Genentech; Takeda
Research Funding - AstraZeneca Spain (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Pfizer; Roche/Genentech; Takeda
 
Nicolas Girard
Employment - AstraZeneca (I)
Consulting or Advisory Role - Abbvie; AMGEN; AstraZeneca; BeiGene; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Ipsen; Janssen; LEO Pharma; Lilly; MSD; Novartis; Pfizer; Roche; Sanofi; Takeda
Research Funding - AstraZeneca (Inst); BMS (Inst); MSDavenir (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Janssen Oncology; Janssen Oncology; Roche
 
Daniel Haggstrom
Consulting or Advisory Role - Bristol-Myers Squibb
 
Manuel Cobo
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen; Kyowa Kirin International; Lilly; MSD; Novartis; Pfizer; Roche; Sanofi; Takeda
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen; Kyowa Kirin International; Lilly; MSD; Novartis; Novocure; Pierre Fabre; Roche; Sanofi; Takeda
 
Maximilian Hochmair
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Lilly; Roche; Takeda
Speakers' Bureau - Lilly; MSD Oncology; Novartis; Roche
 
Yvonne Summers
Honoraria - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; Lilly; MSD; Roche; Takeda
Other Relationship - Roche; Takeda
 
Lizza Hendriks
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); Anheart Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo Europe GmbH (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst); Sanofi (Inst); Summit Therapeutics (Inst); Takeda (Inst)
Speakers' Bureau - AstraZeneca (Inst); Bayer (Inst); Benecke; GlaxoSmithKline (Inst); high5oncology (Inst); Lilly (Inst); Medimix; Medtalks; MSD (Inst); Pfizer (Inst); Sanofi (Inst); Takeda (Inst); VJOncology
Research Funding - Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Gilead Sciences (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Summit Therapeutics (Inst); Takeda (Inst)
Other Relationship - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo Europe GmbH (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); Merck (Inst); Merck Serono (Inst); Mirati Therapeutics (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Takeda (Inst)
(OPTIONAL) Uncompensated Relationships - Dutch Thoracic Group (Inst); ESMO (Inst); European Organisation for Research and Treatment of Cancer (EORTC) (Inst); NVALT; NVALT (Dutch Pulmonary Diseases Association) (Inst)
 
Terufumi Kato
Employment - Lilly (I)
Honoraria - Amgen; Boehringer Ingelheim; Chugai Pharma; Novartis; Pfizer; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; DaiichiSankyo; Johnson & Johnson/Janssen; Merck KGaA; MSD; Novocure
Research Funding - Amgen (Inst); ArriVent Biopharma (Inst); AstraZeneca (Inst); Bayer; BeiGene (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Johnson & Johnson/Janssen (Inst); Lilly (Inst); Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Novocure (Inst); Pfizer (Inst); Regeneron (Inst); Takeda (Inst)
 
Marcello Tiseo
No Relationships to Disclose
 
Davey Daniel
Employment - OneOncology
Research Funding - Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); E.R. Squibb Sons, LLC (Inst); F. Hoffmann LaRoche (Inst); GlaxoSmithKline (Inst); Novartis (Inst)
Other Relationship - Genentech (Inst)
 
Sabeen Mekan
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
 
Riddhi Patel
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
Travel, Accommodations, Expenses - Gilead Sciences
 
Divyadeep Karumanchi
Employment - Gilead Sciences; Novartis
Stock and Other Ownership Interests - Gilead Sciences; Novartis
 
Winnie Weng
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
 
Luis Paz-Ares
Leadership - ALTUM Sequencing; Stab Therapeutics
Stock and Other Ownership Interests - Altum Sequencing; Stab therapeutics
Honoraria - Abbvie; Amgen; AstraZeneca; Bayer; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Gilead Sciences; GlaxoSmithKline; Janssen; Lilly; Medscape; Merck Serono; MSD; Novartis; Pfizer; PharmaMar; Regeneron; Roche/Genentech; Sanofi; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; AstraZeneca; AstraZeneca; Bayer; BMS; GlaxoSmithKline; Janssen; Lilly; Merck; Mirati Therapeutics; MSD; Novartis; Pfizer; Pharmamar; Regeneron; Roche; Sanofi; Takeda
Speakers' Bureau - Amgen; AstraZeneca; BeiGene; BMS; Daiichi Sankyo Europe GmbH; Lilly; Merck Serono; MSD Oncology; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); BMS (Inst); MSD (Inst); Pfizer (Inst); PharmaMar (Inst)
Other Relationship - Amgen (I); Astellas Pharma (I); Crinetics Pharmaceuticals (I); Esteve (I); HUTCHMED (I); Ipsen (I); ITM Isotope Technologies Munich (I); Merck (I); Novartis (I); Pfizer (I); Roche; Roche (I); Sanofi (I); SERVIER (I)